Navigation

EU gives green light to Serono MS drug

Serono will be able to market its MS drug in the European Union Keystone Archive

The Geneva-based biotechnology group, Serono, has been given European Union approval for its multiple sclerosis (MS) drug, Rebif.

This content was published on February 5, 2001 - 09:25

The company said the EU had also recommended the treatment as a first-line therapy for patients with relapsing-remitting MS, the most common form of the disease.

Serono said the Commission's approval was based on a four-year study, which provided clinical evidence that a high dose of Rebif administered as early as possible after the onset of the disease "significantly improves the long-term outlook for the patient".

Serono said Rebif is the only interferon beta product to have gained full approval by the Commission.

The company also announced that it had launched two fertility products in the United States,Ovdrel and Cetrotide.

swissinfo with agencies

This article was automatically imported from our old content management system. If you see any display errors, please let us know: community-feedback@swissinfo.ch

In compliance with the JTI standards

In compliance with the JTI standards

More: SWI swissinfo.ch certified by the Journalism Trust Initiative

Contributions under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.

Share this story

Change your password

Do you really want to delete your profile?